Can-Fite BioPharma American Depositary Shares
CANF
12 hedge funds and large institutions have $1.52M invested in Can-Fite BioPharma American Depositary Shares in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
9% more funds holding
Funds holding: 11 → 12 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
6% less capital invested
Capital invested by funds: $1.62M → $1.52M (-$103K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$351K |
| 2 |
TSS
Two Sigma Securities
New York
|
+$79.2K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$6.69K |
| 4 |
RhumbLine Advisers
Boston,
Massachusetts
|
+$4.12K |
| 5 |
AW
Avion Wealth
The Woodlands,
Texas
|
+$268 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$45.9K |
| 2 |
HF
HRT Financial
New York
|
-$27K |
| 3 |
VF
Virtu Financial
New York
|
-$27K |
CANF Hedge Fund Activity: Q3 2024 in Review
12 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q3 2024, worth a combined $1.52M — down 6.4% from $1.62M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CANF positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $351K. The largest seller was Morgan Stanley, cutting an estimated $45.9K.
- 12 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q3 2024, up from 11 in Q2 2024.
- Funds reported $1.52M of Can-Fite BioPharma American Depositary Shares stock for Q3 2024, down 6.4% quarter-over-quarter.
- 3 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q3 2024 and 2 closed out, a net change of +1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q3 2024 was Armistice Capital, an estimated $351K added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q3 2024 was Morgan Stanley, an estimated $45.9K sold.
Based on aggregated 13F filings for Q3 2024.